Komori
Governance4553TOWA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Independent Officer Notification Form

The independent officer filing was updated because a proposal to appoint an outside director will be submitted to the annual general meeting of shareholders scheduled for 24 June 2026. Taniguchi Soya (谷口宗哉) will be added as a newly appointed independent officer, bringing the total to 5.

Worth reading
33Immaterial
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
5
People (independent officers)
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of independent officers5Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Changes this time

Taniguchi Soya (谷口宗哉) was filed as a newly appointed independent officer. The reason for the filing is that a proposal to appoint an outside officer will be submitted to the annual general meeting of shareholders scheduled for 24 June 2026.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of independent officers5
Changes this timeTaniguchi Soya (谷口宗哉) was filed as a newly appointed independent officer. The reason for the filing is that a proposal to appoint an outside officer will be submitted to the annual general meeting of shareholders scheduled for 24 June 2026.
Items this document does not state (5)
Number of directorsCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because a proposal to appoint an outside officer will be submitted to the annual general meeting of shareholders to be held on 24 June 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Independent Officer Notification Form | TOWA PHARMACEUTICAL CO.,LTD. (4553) timely disclosure | Komori